ACET

NASDAQ 已收盘

Adicet Bio

2.14 USD
▼-0.32-13.01%
盘后 2.20 +2.89%
2026-11-20
市值
$23.04M
市盈率
—
EPS
-8.53
股息率
—
52 周区间
2.12 – 11.15
成交量
765.20K
Beta
1.74
目标价
29.00
52W 低 2.1252W 高 11.15
价格走势

公司简介

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ...